Do Calcium and Vitamin D Supplements Actually Prevent Fractures? What a 153,000-Person Review Shows

A landmark 2026 systematic review and meta-analysis published in The BMJ — covering 69 randomized controlled trials and 153,902 adults — found that calcium supplements, vitamin D supplements, and their combination all provide little to no clinically meaningful reduction in fractures or falls for most older people. That conclusion, drawn from moderate to high certainty evidence, directly challenges decades of routine supplementation advice from clinicians, guideline panels, and regulatory agencies worldwide.

For anyone currently taking calcium or vitamin D to protect their bones, that finding deserves careful unpacking — what the study actually measured, where uncertainty remains, and what the evidence suggests people should do instead.

What the review found at a glance

The table below summarises the three main supplement comparisons from the Massé et al. BMJ meta-analysis:

Supplement	Trials (n)	Participants	Risk Ratio (95% CI)	Evidence Certainty	Effect on Any Fracture
Calcium alone	11	9,067	0.91 (0.81–1.01)	Moderate	Little to no effect
Vitamin D alone	36	92,045	1.00 (0.95–1.06)	High	Little to no effect
Calcium + Vitamin D combined	15	51,126	0.91 (0.84–0.99)	High	Little to no effect

The same pattern held for hip fractures, non-vertebral fractures, vertebral fractures, and falls. Across every primary and secondary outcome, the researchers applied pre-specified thresholds for what would count as a clinically meaningful benefit — and none of the supplement strategies crossed those thresholds.

What exactly was studied, and how?

Systematic review and meta-analysis pools data from multiple independent randomized controlled trials using statistical techniques, allowing researchers to draw conclusions with greater statistical power than any single trial could provide. The Massé et al. review searched Medline, Embase, and CENTRAL databases through February 19, 2025, and also drew on trials from earlier systematic reviews dating to 2014, clinical trial registries, and conference abstracts.

Eligibility was restricted to randomized controlled trials (RCTs) — the study design considered most reliable for establishing whether a treatment works, because participants are randomly assigned to groups, reducing the influence of confounding factors. Trials were included only if they compared calcium, vitamin D, or both against a placebo or no treatment, and only in adults aged 18 or older who were not already receiving drug treatment for osteoporosis.

The primary outcome was the risk of any fracture. Secondary outcomes included hip fracture, non-vertebral fracture, vertebral fracture, the risk of falling at least once, and the total number of falls. Two independent reviewers screened each trial, extracted data, and assessed risk of bias using the Cochrane Risk of Bias tool (version 2). The certainty of evidence was graded using the GRADE framework — the internationally recognised standard for rating how confident researchers can be in a body of evidence.

Critically, the team did not simply ask whether supplements produced any statistically detectable effect. They set thresholds for what absolute risk reductions would be considered clinically important before the analysis began. That methodological choice is significant: a result can be statistically significant while still being too small to matter to a patient. By anchoring conclusions to clinical meaningfulness, the researchers set a higher — and more honest — bar.

Why did so many people believe these supplements worked?

The biological rationale for calcium and vitamin D supplementation rests on the hypothesis that, because calcium is the principal mineral component of bone and vitamin D is required for intestinal calcium absorption and bone metabolism, supplementing both should reduce bone loss and thereby lower fracture risk. That logic is not wrong in principle — calcium and vitamin D genuinely are essential for skeletal health, and severe deficiency of either causes well-documented bone disease.

The problem is that most older adults in high-income countries are not severely deficient. Observational studies — where researchers track what people eat or measure blood levels and then follow health outcomes — consistently showed associations between low vitamin D or low dietary calcium and higher fracture rates. But observational data cannot prove that supplementing corrects the problem. People who take supplements voluntarily also tend to have healthier overall lifestyles, a classic source of confounding.

Earlier meta-analyses had already cast doubt on the approach. A 2019 Oxford-led review in JAMA Network Open that pooled RCT data found no significant reduction in total fracture risk from vitamin D alone or calcium alone. Results for combined supplementation were less consistent, which is part of why guidelines continued to recommend it. The 2026 BMJ review is the most comprehensive synthesis to date, and its use of clinical meaningfulness thresholds — rather than just statistical significance — is what makes its conclusions particularly pointed.

How strong is the evidence, really?

Evidence certainty, assessed using the GRADE framework, reflects the degree of confidence that an estimated effect is close to the true effect. GRADE evaluates multiple dimensions: risk of bias, inconsistency, indirectness, imprecision, and publication bias.

For vitamin D alone — the most commonly prescribed of the three — the certainty rating was high, based on 36 trials and over 92,000 participants. That is the highest possible GRADE rating, meaning further research is very unlikely to change the conclusion. The risk ratio of 1.00 (95% CI 0.95–1.06) for any fracture is about as close to a null result as clinical research produces.

For combined calcium and vitamin D — the combination most often cited in guidelines — certainty was also high, from 15 trials and more than 51,000 participants. The risk ratio of 0.91 (95% CI 0.84–0.99) technically crosses the threshold of statistical significance at the lower bound, but the absolute risk reduction did not meet the pre-specified threshold for clinical importance. Even if the effect is real, it is too small to meaningfully change outcomes for individual patients.

For calcium alone, certainty was moderate — one step below high — based on 11 trials and around 9,000 participants. Moderate certainty means the true effect is probably close to the estimate, but some possibility of a meaningful difference remains. The smaller evidence base here warrants more caution than the vitamin D findings.

The findings were also tested across multiple subgroup analyses — by age, sex, history of previous fractures, history of previous falls, and baseline dietary calcium intake — and remained broadly consistent throughout. That robustness strengthens confidence in the overall picture.

Are there people for whom supplements might still make sense?

The researchers are explicit that their conclusions come with important caveats, and those caveats matter clinically.

The review excluded people already receiving drug treatment for osteoporosis — medications such as bisphosphonates, denosumab, or teriparatide. In those patients, calcium and vitamin D are often prescribed as adjuncts to the primary therapy, not as standalone fracture prevention. The evidence reviewed here does not address that use case, and stopping supplementation in someone already on osteoporosis medication without specialist guidance would be premature.

The evidence for people at especially high risk — those in residential care, those with established severe osteoporosis, or those with documented deficiency — was also limited for some outcomes, particularly for calcium monotherapy and combined supplementation. The BMJ editorial linked to the paper explicitly calls for more rigorous, well-powered trials in high-risk populations before drawing firm conclusions for those groups.

People with specific bone disorders, malabsorption syndromes, or conditions that impair vitamin D metabolism — such as chronic kidney disease or certain gastrointestinal diseases — have different physiological needs. The population in most of the included trials was community-dwelling (87%) and not at high fracture or fall risk (73%), a profile that does not represent everyone who takes these supplements.

The evidence does not support routine supplementation for the general older adult population seeking fracture prevention. It does not say supplements are useless in every clinical scenario.

What about safety — are there any harms from taking these supplements?

The 2026 review focused on efficacy rather than safety, but the broader literature on supplement harms is worth noting. The BMJ rapid response from rehabilitation clinicians highlighted that prolonged calcium supplement use is associated with gastrointestinal adverse effects, including constipation and, in some studies, increased risk of kidney stones. High-dose calcium supplementation has also been linked in some analyses to cardiovascular events, though that association remains debated.

Vitamin D toxicity from supplementation is rare at typical doses but possible at very high doses, producing hypercalcaemia and associated symptoms. For most people taking standard over-the-counter doses, the safety profile is acceptable — but if the supplements are not providing meaningful fracture protection, the risk-benefit calculation shifts.

What does the evidence say about alternatives?

The BMJ editorial authors and the rehabilitation clinicians who responded to the paper converge on the same recommendation: redirect attention and resources toward exercise-based interventions.

Balance training improves postural stability, proprioception, and neuromuscular coordination — the physical systems that determine whether a person recovers from a stumble or falls. Multiple systematic reviews cited in the BMJ rapid response confirm that exercise, particularly programs combining balance and resistance components, is among the most effective interventions for reducing falls in older adults.

Resistance exercise — progressive loading of muscles against external force, such as weights, resistance bands, or bodyweight — builds the muscle strength that supports joints and absorbs impact forces. Strength loss (sarcopenia) is a major independent risk factor for both falls and fractures, and it is not corrected by calcium or vitamin D tablets.

Multifactorial programs that combine exercise with home hazard assessment (removing trip hazards, improving lighting) and individualised education about fall risk have shown particularly meaningful results. These approaches address the actual mechanisms of falling — neuromuscular function, environmental hazards, medication side effects that impair balance — rather than attempting to modify bone density through supplementation.

The BMJ rapid response from Yi Feng at Hangzhou Rehabilitation Hospital put it directly: "Neuromuscular impairment cannot simply be corrected biochemically; structured exercise, including balance training, progressive resistance, and gait retraining, directly targets fall mechanisms." That framing captures why the supplement approach, however biologically plausible, may have been solving the wrong problem.

What should clinicians and guideline panels do now?

The Massé et al. research team is unambiguous in their recommendation: the evidence "does not support routine supplementation with calcium or vitamin D, or combined supplementation to prevent fractures and falls," and clinicians, guideline panels, and regulatory agencies "should re-evaluate their general recommendations for calcium and vitamin D supplementation in light of current evidence."

That is a significant call to action. Many national guidelines — including those from osteoporosis societies and geriatric medicine bodies — currently recommend vitamin D supplementation for older adults as a matter of routine. Prescriptions for calcium and vitamin D have risen substantially since the early 2000s, meaning a large number of patients are taking supplements that this evidence suggests provide little benefit for fracture prevention.

Guideline revision is a slow process, and some bodies will likely wait for additional high-risk population data before making changes. Clinicians in the meantime face a practical question: what to tell patients who are currently taking these supplements specifically for bone protection.

A reasonable interpretation of the current evidence is that stopping routine supplementation in community-dwelling older adults without documented deficiency or osteoporosis drug therapy is defensible and consistent with the data. Patients taking supplements as part of osteoporosis drug treatment, or who have documented vitamin D deficiency, should discuss any changes with their prescribing clinician rather than acting unilaterally.

What gaps remain in the research?

Despite the size and quality of this review, several questions remain genuinely open.

The evidence base for calcium monotherapy is smaller than for vitamin D — 11 trials and roughly 9,000 participants, compared to 36 trials and 92,000 for vitamin D alone. The moderate certainty rating for calcium reflects that gap, and more trials would sharpen the estimate considerably.

High-risk populations — people in residential care, those with very low baseline vitamin D levels, those with a recent fracture — were underrepresented in the included trials. The editorial authors specifically flag this as a priority for future research. It remains possible that a subgroup exists for whom supplementation provides meaningful benefit, but the current data cannot identify that group with confidence.

The optimal dose and formulation of vitamin D also remain uncertain. Most trials used daily oral supplementation, but some used intermittent high-dose regimens. There is some evidence that very high intermittent doses may actually increase fall risk, adding further complexity to the picture.

Finally, the interaction between supplementation and dietary intake is not fully resolved. People with very low dietary calcium or very low sun exposure may respond differently to supplementation than those with adequate baseline levels. Personalised approaches based on measured deficiency, rather than population-wide routine supplementation, may eventually prove more productive than the blanket strategies tested in most trials.

The practical takeaway

Nearly one in three adults aged 65 and older falls each year, and falls are the primary cause of both fatal and non-fatal injuries in that age group. The public health stakes of getting fall and fracture prevention right are enormous. For decades, calcium and vitamin D supplements have been a central pillar of that prevention effort — widely recommended, widely prescribed, and widely purchased.

The 2026 BMJ meta-analysis does not say these supplements are harmful for most people. It says they are not doing the job they were prescribed to do, at least not for the general older adult population. That distinction matters because it redirects the conversation toward what actually works: structured exercise that builds strength, improves balance, and directly addresses the neuromuscular mechanisms that determine whether a fall happens and whether it results in a fracture.

For readers interested in related evidence on supplements and musculoskeletal health, the site has previously covered natural supplement options for knee arthritis pain and blood pressure supplements with evidence behind them — areas where the evidence picture is similarly detailed and context-dependent.

The core lesson from the calcium and vitamin D story applies broadly to supplement science: biological plausibility is not the same as clinical efficacy. A nutrient can be genuinely essential for a physiological process while supplementing it above baseline levels produces no measurable health benefit in people who are not deficient. That distinction — between correcting deficiency and optimising health in replete individuals — is one the supplement industry has rarely been required to confront at this scale of evidence.